Big pharma’s unorthodox strategy

Amy Scott Jun 30, 2006
HTML EMBED:
COPY

Big pharma’s unorthodox strategy

Amy Scott Jun 30, 2006
HTML EMBED:
COPY

TEXT OF STORY

SCOTT JAGOW: Another major drug patent expires today. This one for the popular anti-depressant, Zoloft. It’s made by Pfizer. Last week, Merck lost the patent on the cholesterol-fighting drug Zocor. Marketplace’s Amy Scott tells us about life after patents for these companies.


AMY SCOTT: When a patent expires, analysts say a drug maker can lose up to 90 percent of its market share within months to generic competitors.

Pfizer plans to fight back by selling its own generic version of Zoloft as well as the name brand.

Merck is trying a similar tactic with Zocor, by slashing prices for large insurers.

It might seem counterintuitive for a company to undercut its own prices, but industry analyst Hemant Shah says drug makers don’t have a choice.

HEMANT SHAH: By launching their own generic versions, either on their own, or through another generic company, they can at least keep some of that profit, which otherwise would all go to generic companies.

Consumer advocates worry the practice could drive prices up.

The Federal Trade Commission is looking into whether brand name manufacturers are stifling competition by cutting into generic drug maker’s profits.

In New York, I’m Amy Scott for Marketplace.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.

Raise a glass to Marketplace!

Just $7/month gets you a limited edition KaiPA pint glass. Plus bragging rights that you support independent journalism.
Donate today to get yours!